- Home
- LKCO vs APRE Comparison
LKCO vs APRE Comparison
Compare LKCO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LKCO
- APRE
- Stock Information
- Founded
- LKCO 2009
- APRE 2006
- Country
- LKCO China
- APRE United States
- Employees
- LKCO N/A
- APRE N/A
- Industry
- LKCO EDP Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LKCO Technology
- APRE Health Care
- Exchange
- LKCO Nasdaq
- APRE Nasdaq
- Market Cap
- LKCO 11.9M
- APRE 13.5M
- IPO Year
- LKCO N/A
- APRE 2019
- Fundamental
- Price
- LKCO $0.81
- APRE $1.80
- Analyst Decision
- LKCO
- APRE Strong Buy
- Analyst Count
- LKCO 0
- APRE 2
- Target Price
- LKCO N/A
- APRE $15.50
- AVG Volume (30 Days)
- LKCO 134.3K
- APRE 21.0K
- Earning Date
- LKCO 10-22-2024
- APRE 05-13-2025
- Dividend Yield
- LKCO N/A
- APRE N/A
- EPS Growth
- LKCO N/A
- APRE N/A
- EPS
- LKCO N/A
- APRE N/A
- Revenue
- LKCO $5,389,818.00
- APRE $1,502,581.00
- Revenue This Year
- LKCO N/A
- APRE N/A
- Revenue Next Year
- LKCO N/A
- APRE N/A
- P/E Ratio
- LKCO N/A
- APRE N/A
- Revenue Growth
- LKCO N/A
- APRE 157.63
- 52 Week Low
- LKCO $0.80
- APRE $1.85
- 52 Week High
- LKCO $7.68
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- LKCO 19.43
- APRE 26.70
- Support Level
- LKCO $1.39
- APRE $1.85
- Resistance Level
- LKCO $1.74
- APRE $2.30
- Average True Range (ATR)
- LKCO 0.34
- APRE 0.16
- MACD
- LKCO -0.13
- APRE -0.01
- Stochastic Oscillator
- LKCO 2.81
- APRE 2.50
About LKCO Luokung Technology Corp
Luokung Technology Corp is a spatial-temporal intelligent big data services company, as well as a provider of LBS for various industries in China. It has established city-level and industry-level holographic spatial-temporal digital twin systems and actively serves industries including smart transportation (autonomous driving, smart highway and vehicle-road collaboration), natural resource asset management (carbon neutral and environmental protection remote sensing data service), and LBS smart industry applications (mobile Internet LBS, smart travel, smart logistics, new infrastructure, smart cities, emergency rescue, among others).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.